Biowaiver monographs for immediate release solid oral dosage forms: acetaminophen (paracetamol)

Area of Science:

• Pharmaceutical Sciences
• Pharmacokinetics
• Drug Formulation

Background:

• Acetaminophen (paracetamol) is classified as a Biopharmaceutics Classification System (BCS) Class III compound.
• While absorption extent is generally consistent, formulation differences can affect absorption rate, notably with sodium bicarbonate potentially increasing gastric emptying.
• Health authorities have recognized rapid-onset acetaminophen products, indicating therapeutic irrelevance of minor absorption rate variations.

Purpose of the Study:

• To review literature on acetaminophen properties relevant to the Biopharmaceutics Classification System (BCS).
• To evaluate the scientific justification for granting biowaivers for immediate-release (IR) acetaminophen solid oral dosage forms.
• To establish criteria for accepting biowaivers based on dissolution and excipient profiles.

Main Methods:

• Literature review of acetaminophen's biopharmaceutical properties.
• Analysis of existing Marketing Authorizations (MAs) for acetaminophen products with rapid onset of action.
• Evaluation of in vitro dissolution data and bioequivalence (BE) guidelines.

Main Results:

• Acetaminophen is confirmed as a BCS Class III drug.
• Differences in absorption rates between brands are generally considered therapeutically insignificant by regulatory bodies.
• In vitro dissolution data can reliably declare bioequivalence for acetaminophen formulations under specific conditions.

Conclusions:

• Biowaivers for immediate-release (IR) acetaminophen solid oral drug products are scientifically justified.
• Acceptance requires the test product to contain usual amounts of specified excipients and demonstrate rapid dissolution.
• Similarity of dissolution profiles to the reference product is a key criterion for biowaiver approval.